Aug 03, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: 2022 Wedbush PacGrow Healthcare Conference , “A View to a Kill(er Cell) – Part 1” panel on
Mar 16, 2022
Proceeds to support 2seventy bio’s pipeline of novel cell therapy programs Financing, combined with reduced net cash spend and ABECMA commercial progress, supports extension of cash runway into 2025 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2022-- 2seventy bio, Inc .
Feb 14, 2022
Steven Bernstein , M.D. appointed to chief medical officer Susan Abu-Absi , Ph.D. promoted to chief technology & manufacturing officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2022-- 2seventy bio, Inc . (NASDAQ: TSVT) announced that Steven Bernstein , M.D.